TRVI - Trevi Therapeutics, Inc.
| Previous Close | 5.1800 |
| Open | 4.8400 |
| Bid | 4.8500 x 900 |
| Ask | 5.2300 x 900 |
| Day's Range | 4.8400 - 5.2300 |
| 52 Week Range | 2.6500 - 10.6200 |
| Volume | 1,888 |
| Avg. Volume | 13,685 |
| Market Cap | 86.676M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.7410 |
| Earnings Date | Aug 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
- Zacks
Trevi Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Trevi Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
Phase 2b/3 PRISM trial: The ongoing PRISM trial is a randomized, double-blind, placebo controlled, two-arm treatment study that is designed to evaluate the safety and anti-pruritic efficacy of nalbuphine ER in approximately 240 patients with severe pruritus from PN in approximately 50 centers in the U.S. and Europe. The pace of enrollment has been slower than anticipated primarily due to competition from other clinical trials and slower than planned site start-ups in Europe. As a result, the Company expects to report top-line data from the PRISM trial in the second half of 2020.
- GlobeNewswire
Trevi Therapeutics to Present at Stifel Healthcare Conference
A live webcast of the presentation can be accessed by visiting ‘News & Events’ in the Investor & News section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will be available for 90 days on the Company's website following the conference. The corporate presentation that the Company intends to present with and at the time of the live webcast will be posted to its website under ‘Investor & News’.
- Simply Wall St.
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jennifer L. Good, President and Chief Executive Officer of Trevi Therapeutics, will participate in a panel discussion, as well as host investor meetings, at the BTIG Pain / Pruritus Management Forum being held on Wednesday, September 11, 2019 in New York City. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
- GlobeNewswire
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
“We are pleased with the progress we made during the first half of 2019 advancing the development of nalbuphine ER and positioning Trevi for several important clinical milestones later this year and in 2020,” said Jennifer L. Good, President and CEO of Trevi Therapeutics. “We remain on track to report top-line data from both our Phase 2b/3 PRISM trial of nalbuphine ER in patients with prurigo nodularis and from our Phase 2 trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) in the first half of 2020. Continued patient enrollment in the Phase 2b/3 PRISM trial: The ongoing PRISM trial is a randomized, double-blind, placebo controlled, two-arm treatment study that is designed to evaluate the safety and anti-pruritic efficacy of nalbuphine ER in approximately 240 prurigo nodularis (PN) patients with severe pruritus from PN in approximately 50 centers in the U.S. and Europe.
- Simply Wall St.
Have Insiders Been Buying Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GlobeNewswire
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the quarter ended March 31, 2019, as well as recent business highlights. “The successful completion of our IPO enables Trevi to continue development of nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease,” said Jennifer L. Good, President and CEO of Trevi Therapeutics.
- Benzinga
BMO Sees Compelling Valuation For Trevi Therapeutics At Current Levels
Trevi's key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism of treating various chronic pruritus and cough conditions, analyst Nachman said in a Monday morning note. The pipeline asset has shown positive clinical data in a large Phase 2b/3 trial in uremic pruritus associated with chronic kidney disease, and in a smaller Phase 2 study in prurigo nodularis, the lead indication, the asset achieved statistical significance in a post-hoc analysis for patients who completed the study on the higher dose, Nachman noted. The analyst said prurigo nodularis is an area of high unmet need with a sizeable market opportunity.
- GlobeNewswire
Trevi Therapeutics Announces Pricing of Initial Public Offering
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at an initial public offering price of $10.00 per share, for gross proceeds of $55 million. In addition, Trevi has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Trevi.
- Benzinga
Trevi Therapeutics IPO: What You Need To Know
Trevi Therapeutics, Inc. will issue nearly 4.7 million shares on the Nasdaq under ticker TRVI, according to the firm’s S-1 filing. Lead underwriters include SVB Leerink, Stifel and BMO Capital Markets. The Connecticut biotech targets chronic pruritis, chronic cough related to idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia related to Parkinson’s disease.
